Schito A M, Schito G C, Debbia E, Russo G, Liñares J, Cercenado E, Bouza E
Istituto di Microbiologia, Facoltà di Medicina, Università di Genova, Italy.
J Chemother. 2003 Jun;15(3):226-34. doi: 10.1179/joc.2003.15.3.226.
Antibacterial resistance was evaluated among Streptococcus pneumoniae (n=252) and Haemophilus influenzae (n=202) from two centres in Spain (Barcelona and Madrid) and two centres in Italy (Genoa and Catania) collected during 1999-2000 as part of the ongoing PROTEKT (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin) international surveillance program. Pneumococcal nonsusceptibility to penicillin G was found to be considerably higher in Spain (53.4%) than in Italy (15.1%), whereas erythromycin A resistance was higher in Italy (42.9%) than in Spain (28.6%). Among macrolide-resistant isolates investigated for resistance genes, the prevalence of mefA was higher among isolates from Italy (20/51, 39.2%) than among Spanish isolates (2/38, 5.3%). All other macrolide-resistant isolates possessed ermB. Telithromycin possessed good anti-pneumococcal activity against isolates from both countries (MIC90 0.03 mg/L [Spain]; 0.25 mg/L [Italy]), irrespective of resistance to other antibacterials. Beta-lactamase production among H. influenzae was low: Spain, 10.9%; Italy, 1.8%. With the exception of ampicillin and co-trimoxazole, all H. influenzae isolates were highly susceptible to the antibacterials tested, and all were inhibited by telithromycin at a concentration of < or = 2 mg/L. The findings of PROTEKT 1999-2000 highlight the importance of local resistance patterns in guiding the choice of empirical antibacterials for community-acquired respiratory tract infections.
作为正在进行的PROTEKT(酮内酯类药物泰利霉素的前瞻性耐药菌追踪与流行病学研究)国际监测项目的一部分,对1999年至2000年期间从西班牙的两个中心(巴塞罗那和马德里)以及意大利的两个中心(热那亚和卡塔尼亚)收集的252株肺炎链球菌和202株流感嗜血杆菌进行了抗菌药物耐药性评估。结果发现,西班牙肺炎链球菌对青霉素G的不敏感性(53.4%)显著高于意大利(15.1%),而意大利红霉素A耐药性(42.9%)高于西班牙(28.6%)。在对耐药基因进行研究的大环内酯类耐药菌株中,意大利菌株(20/51,39.2%)中mefA的流行率高于西班牙菌株(2/38,5.3%)。所有其他大环内酯类耐药菌株均携带ermB。泰利霉素对来自两国的菌株均具有良好的抗肺炎链球菌活性(西班牙的MIC90为0.03mg/L;意大利为0.25mg/L),无论对其他抗菌药物的耐药情况如何。流感嗜血杆菌中β-内酰胺酶的产生率较低:西班牙为10.9%;意大利为1.8%。除氨苄西林和复方新诺明外,所有流感嗜血杆菌分离株对所测试的抗菌药物均高度敏感,并且所有菌株在浓度≤2mg/L时均被泰利霉素抑制。1999 - 2000年PROTEKT研究结果突出了当地耐药模式在指导社区获得性呼吸道感染经验性抗菌药物选择中的重要性。